For individuals who have not made the sort of risk-averse decisions in their lives that lead to better jobs and wealth accumulation, making treatment decisions after a cancer diagnosis can be very difficult, said Amy Davidoff, PhD, MS, senior research scientist in public health at the Yale School of Public Health
For individuals who have not made the sort of risk-averse decisions in their lives that lead to better jobs and wealth accumulation, making treatment decisions after a cancer diagnosis can be very difficult, said Amy Davidoff, PhD, MS, senior research scientist in public health at the Yale School of Public Health
Transcript (slightly modified for readability)
How can providers help patients with cancer make treatment decisions?
People are making choices all throughout their lives. Some people are much more risk averse, they invest in their education, they have better jobs, they accumulate wealth and at the end of their life they are able to tap into those resources, they are able to understand therapeutic choices, they're able to use their resources to make choices that are best for them and their family. A lot of people though, have not made those kind of risk-averse choices over time and then all of a sudden they are faced with this decision—it's a very difficult one.
You have a lot of individuals, and I think this may be the root of a lot of disparities concerns: low-income individuals, oftentime minorities, have not had the opportunity to accumulate wealth throughout their lifetime. And so when it comes to end-of-life decision choose to not get therapy at all and you see that in the patterns of care that we observe and research.
And I think it's going to be a huge challenge as a society to not only correct those disparities in resources at the time a treatment choice is faced, but also think about ways to improve education and opportunities earlier on in life so we don't have these sort of disparities of position when you're faced with that end-of-life choice.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Technology Takes Center Stage at the 2025 AAD Annual Meeting
March 14th 2025The role of artificial intelligence, DataDerm, and telehealth in advancing dermatology care was discussed throughout the meeting, with experts highlighting their potential regarding patient access and health equity.
Read More